UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PI(3)King apart PTEN's Role in Cancer

Clinical cancer research, 2010-09, Vol.16 (17), p.4325-4330

2010

Volltextzugriff (PDF)

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy

Nature communications, 2021-02, Vol.12 (1), p.832-17, Article 832

2021

Volltextzugriff (PDF)

Tumor microenvironment as a therapeutic target in cancer

Pharmacology & therapeutics (Oxford), 2021-05, Vol.221, p.107753-107753, Article 107753

2021

Volltextzugriff (PDF)

EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin β1-FAK activation

Nature communications, 2022-05, Vol.13 (1), p.2543-2543, Article 2543

2022

Volltextzugriff (PDF)

TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis

The Journal of clinical investigation, 2021-04, Vol.131 (8), p.1-13

2021

Volltextzugriff (PDF)

Exosomes in cancer development, metastasis, and immunity

Biochimica et biophysica acta. Reviews on cancer, 2019-04, Vol.1871 (2), p.455-468

2019

Volltextzugriff (PDF)

The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1

Cancer cell, 2022-01, Vol.40 (1), p.36-52.e9

2022

Volltextzugriff (PDF)

Deubiquitination and Stabilization of PD-L1 by CSN5

Cancer cell, 2016-12, Vol.30 (6), p.925-939

2016

Volltextzugriff (PDF)

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Nature communications, 2016-08, Vol.7 (1), p.12632-11, Article 12632

2016

Volltextzugriff (PDF)

The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis

Journal of biomedical science, 2020-07, Vol.27 (1), p.77-77, Article 77

2020

Volltextzugriff (PDF)

Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells

Cancer research (Chicago, Ill.), 2018-05, Vol.78 (9), p.2248-2261

2018

Volltextzugriff (PDF)

Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells

Cancer research (Chicago, Ill.), 2017-10, Vol.77 (19), p.5374-5383

2017

Volltextzugriff (PDF)

14-3-3ζ as a prognostic marker and therapeutic target for cancer

Expert opinion on therapeutic targets, 2010-12, Vol.14 (12), p.1343-1354

2010

Volltextzugriff (PDF)

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

Nature medicine, 2011-04, Vol.17 (4), p.461-469

2011

Volltextzugriff (PDF)

PTEN, PIK3CA, p-AKT, and p-p70S6K Status: Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer

The American journal of pathology, 2010-10, Vol.177 (4), p.1647-1656

2010

Volltextzugriff (PDF)

Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1

Cancer discovery, 2022-07, Vol.12 (7), p.1742-1759

2022

Volltextzugriff (PDF)

Molecular mechanisms of erbB2-mediated breast cancer chemoresistance

Advances in experimental medicine and biology, 2007, Vol.608, p.119

2007

Volltextzugriff (PDF)

Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?

Cell & bioscience, 2019-10, Vol.9 (1), p.82-82, Article 82

2019

Volltextzugriff (PDF)

Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

Nature clinical practice. Oncology, 2006-05, Vol.3 (5), p.269-280

2006

Volltextzugriff (PDF)

Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells

PloS one, 2010-10, Vol.5 (10), p.e13390-e13390

2010

Volltextzugriff (PDF)

Targeting Src family kinases in anti-cancer therapies: turning promise into triumph

Trends in pharmacological sciences (Regular ed.), 2012-03, Vol.33 (3), p.122-128

2012

Volltextzugriff (PDF)

GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancer

Nature communications, 2024-03, Vol.15 (1), p.2132-2132, Article 2132

2024

Volltextzugriff (PDF)

Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma

Nature communications, 2024-02, Vol.15 (1), p.1009-1009, Article 1009

2024

Volltextzugriff (PDF)

Src Family Kinases as Novel Therapeutic Targets to Treat Breast Cancer Brain Metastases

Cancer research (Chicago, Ill.), 2013-09, Vol.73 (18), p.5764-5774

2013

Volltextzugriff (PDF)

Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy

Journal of clinical oncology, 2011-08, Vol.29 (23), p.3126-3132

2011

Volltextzugriff (PDF)

1 – 25 von 468

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(432)
Mit Volltextzugriff
(426)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(92)
Oncogene
(21)
Cancer
(13)
Clinical Cancer Research
(13)
Advances In Experimental Medicine And Biology
(11)
Breast Cancer Chemosensitivity
(11)
Cancer Cell
(11)
Cancer Biology & Therapy
(9)
The Journal Of Biological Chemistry
(8)
Nature Communications
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

PI(3)King apart PTEN's Role in Cancer

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy

Tumor microenvironment as a therapeutic target in cancer

EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin β1-FAK activation

TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis

Exosomes in cancer development, metastasis, and immunity

The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1

Deubiquitination and Stabilization of PD-L1 by CSN5

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis

Oncogenic Kinase-Induced PKM2 Tyrosine 105 Phosphorylation Converts Nononcogenic PKM2 to a Tumor Promoter and Induces Cancer Stem-like Cells

Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells

14-3-3ζ as a prognostic marker and therapeutic target for cancer

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

PTEN, PIK3CA, p-AKT, and p-p70S6K Status: Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer

Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1

Molecular mechanisms of erbB2-mediated breast cancer chemoresistance

Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?

Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells

Targeting Src family kinases in anti-cancer therapies: turning promise into triumph

GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancer

Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma

Src Family Kinases as Novel Therapeutic Targets to Treat Breast Cancer Brain Metastases

Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy

Suchergebnisse filtern